Open Access Highly Accessed Open Badges Research article

The Belgian MIRA (MabThera In Rheumatoid Arthritis) registry: clues for the optimization of rituximab treatment strategies

Bert Vander Cruyssen1*, Patrick Durez2, Rene Westhovens3, Marie-Joelle Kaiser4, Ilse Hoffman5, Filip De Keyser1 and The MIRA Study Group

Author Affiliations

1 Department of Rheumatology, Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium

2 Department of Rheumatology, Cliniques Universitaires Saint-Luc, Avenue Hippocrate, 10, 1200 Brussels, Belgium

3 Department of Rheumatology, University Hospitals KULeuven, Herestraat 49, 3000 Leuven, Belgium

4 Department of Rheumatology, University Hospital Liège, Domaine universitaire B35, 4000 Liège, Belgium

5 Department of Rheumatology, GZA St-Augustinus Hospital Antwerp, Oosterveldlaan 24, 2610 Wilrijk, Belgium

For all author emails, please log on.

Arthritis Research & Therapy 2010, 12:R169  doi:10.1186/ar3129

Published: 10 September 2010



This study describes the results of the Belgian 'MabThera In Rheumatoid Arthritis (MIRA)' registry: effectiveness, safety and evaluation of the current retreatment practice on the background of the Belgian reimbursement criteria for rituximab.


All Belgian rheumatologists had the possibility to participate in the study. Patients entered the registry in November 2006 and the entry is still open.


By mid-September 2009, 401 patients had entered the registry with a mean follow-up time of 70 weeks. Overall, DAS28-ESR decreased from 6.0 at baseline to 4.2 at week 16. Further decrease of disease activity was observed at the end of year 1 and year 2 with mean DAS28-ESR of 4.0 and 3.7 at these respective time points. More than 80% of patients showed a EULAR response at week 16. Patients could be retreated if they had DAS scores of > 3.2 at least 6 months after the previous course. Second and third courses were given in 224 and 104 patients, respectively. At month 6 after the second course, significantly lower DAS28-ESR values were observed compared to the first course. This was especially the case for patients who were retreated before they showed an obvious flare (DAS increase > 1.2).


This study describes the follow-up of a daily clinical practice cohort of 401 RA patients with long-standing refractory disease treated with rituximab. Relatively high DAS28 values at the start of each retreatment, compared to values 6 months after each treatment course, were noted. Moreover, further decrease of DAS28 scores after the second course was significantly more pronounced in those patients who didn't show an obvious flare. These two elements suggest that treatment of RA patients with rituximab could be optimized by earlier retreatment.